Some generic industry agenda items have become generic versus brand battles, but pharmacy benefit managers (PBMs) and healthcare purchasers hope that their support of generic objectives shows that proposals such as a regulatory pathway for biosimilars would benefit not only the generic industry, but consumers, patients and payers.